FDA gives green light to Aevice Health for pediatric wearable stethoscope technology
The AeviceMD, a groundbreaking smart wearable stethoscope developed by Aevice Health, has been granted FDA 510(k) clearance, making it the first device of its kind approved for home-based respiratory monitoring for children aged 3 and above.
This innovative device, designed for pediatric respiratory monitoring, is set to transform the healthcare landscape, allowing for early detection of respiratory exacerbations by clinicians and enabling remote patient monitoring applications.
The AeviceMD's clinically validated AI and child-friendly design provide objective data for monitoring patients with chronic respiratory diseases from the comfort of their homes. This not only empowers families but also reduces the burden on hospitals and traditional clinical settings.
Adrian Ang, CEO of Aevice Health, expressed his excitement about this regulatory milestone, stating that it extends the company's reach to vulnerable patient groups, including young children. Following this clearance, Aevice Health plans to accelerate its commercialization efforts and increase its focus on enterprise partnerships.
The AeviceMD is already in use in leading hospitals in both the U.S. and Singapore, demonstrating its potential to revolutionize hospital-at-home care. As a hospital-at-home tool, the AeviceMD supports earlier interventions, reduces readmissions, and extends care beyond traditional clinical settings.
Aevice Health's success is not limited to the AeviceMD. The company recently closed its Seed Plus round, led by Coronet Ventures, the U.S. venture arm of Cedars-Sinai Intellectual Property. The round also saw participation from institutional and corporate investors including SEEDS Capital, East Ventures, Denka Company, A&D Company, and Elev8 VC.
In addition to its commercialization efforts, Aevice Health aims to increase its involvement in home care programs following the paediatric clearance of the AeviceMD. The company is embedded in digital health innovation networks, such as i2.JP, which includes partners like startups, healthcare providers, local governments, and academia interested in remote medicine, digital health, wearable devices, and vital sensing technologies.
However, as of the latest data in July 2025, specific enterprise partnerships or defined home care programs for AeviceMD were not publicly disclosed in the available sources. More detailed partnership or program information may reside directly with Aevice Health or partner announcements beyond these sources.
In conclusion, the FDA clearance of the AeviceMD marks a significant step forward in the field of pediatric respiratory monitoring, enabling home-based care for young patients. With its focus on enterprise partnerships and home care programs, Aevice Health is poised to make a lasting impact on the healthcare industry.
Medical plastics play a crucial role in the construction of the AeviceMD, as it is a compact smart wearable stethoscope. The device's child-friendly design and technology, which includes clinically validated AI, are part of the digital health landscape that is transforming health-and-wellness for patients with chronic respiratory diseases. Furthermore, Aevice Health, in seeking to make a lasting impact in the healthcare industry, has secured significant funding from various investors in the finance sector, enabling them to accelerate their commercialization efforts and increase their focus on enterprise partnerships.
